Three 1 mL doses of Rabies vaccine and two JE vaccine + Three 0.5 mL doses of Rabies vaccine and two JE vaccine + Three 0.1mL doses of Rabies Vaccine and two JE vaccine + Two 0.1mL doses of Rabies vaccine and two JE vaccine + Two doses of JE vaccine
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Rabies
Conditions
Rabies, Japanese Encephalitis, Pre-Exposure Prophylaxis
Trial Timeline
Aug 1, 2002 → Sep 1, 2004
NCT ID
NCT00694460About Three 1 mL doses of Rabies vaccine and two JE vaccine + Three 0.5 mL doses of Rabies vaccine and two JE vaccine + Three 0.1mL doses of Rabies Vaccine and two JE vaccine + Two 0.1mL doses of Rabies vaccine and two JE vaccine + Two doses of JE vaccine
Three 1 mL doses of Rabies vaccine and two JE vaccine + Three 0.5 mL doses of Rabies vaccine and two JE vaccine + Three 0.1mL doses of Rabies Vaccine and two JE vaccine + Two 0.1mL doses of Rabies vaccine and two JE vaccine + Two doses of JE vaccine is a phase 2 stage product being developed by Novartis for Rabies. The current trial status is completed. This product is registered under clinical trial identifier NCT00694460. Target conditions include Rabies, Japanese Encephalitis, Pre-Exposure Prophylaxis.
What happened to similar drugs?
2 of 15 similar drugs in Rabies were approved
Approved (2) Terminated (0) Active (13)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00694460 | Phase 2 | Completed |
Competing Products
20 competing products in Rabies